1. Novartis Institutes for BioMedical Research, East Hanover, NJ;
2. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
3. Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, PA;
4. Department of Pediatrics, University of Michigan, Ann Arbor, MI;
5. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;
6. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA;
7. Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, UT;
8. Children’s Mercy Hospital, Kansas City, MO;
9. Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia;
10. Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;
11. Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada;
12. Department of Haematology and Oncology, University Hospital of Cologne, Cologne, Germany;
13. Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;
14. Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute, Emory University, Atlanta, GA;
15. Novartis Pharma AG, Basel, Switzerland;
16. Salt River Integrated Bioanalysis GmbH, Basel, Switzerland;
17. Novartis Pharmaceuticals Corporation, East Hanover, NJ;
18. Department of Pediatrics, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; and
19. Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA